166 related articles for article (PubMed ID: 17169785)
1. Cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab: prophylaxis vs. pre-emptive strategies for prevention.
Worth LJ; Thursky KA
Leuk Lymphoma; 2006 Dec; 47(12):2435-6. PubMed ID: 17169785
[No Abstract] [Full Text] [Related]
2. Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir.
Laurenti L; Piccioni P; Cattani P; Cingolani A; Efremov D; Chiusolo P; Tarnani M; Fadda G; Sica S; Leone G
Haematologica; 2004 Oct; 89(10):1248-52. PubMed ID: 15477211
[TBL] [Abstract][Full Text] [Related]
3. The prevention of alemtuzumab-induced cytomegalovirus reactivation: still a matter of debate. An update from Pesaro experience with once weekly intravenous ganciclovir.
Isidori A; Visani G
Leuk Lymphoma; 2009 Feb; 50(2):294-6. PubMed ID: 19197728
[No Abstract] [Full Text] [Related]
4. Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.
O'Brien S; Ravandi F; Riehl T; Wierda W; Huang X; Tarrand J; O'Neal B; Kantarjian H; Keating M
Blood; 2008 Feb; 111(4):1816-9. PubMed ID: 18039954
[TBL] [Abstract][Full Text] [Related]
5. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.
Montillo M; Tedeschi A; Miqueleiz S; Veronese S; Cairoli R; Intropido L; Ricci F; Colosimo A; Scarpati B; Montagna M; Nichelatti M; Regazzi M; Morra E
J Clin Oncol; 2006 May; 24(15):2337-42. PubMed ID: 16618945
[TBL] [Abstract][Full Text] [Related]
6. An observational study of once weekly intravenous ganciclovir as CMV prophylaxis in heavily pre-treated chronic lymphocytic leukemia patients receiving subcutaneous alemtuzumab.
Visani G; Mele A; Guiducci B; D'Adamo F; Leopardi G; Barulli S; Malerba L; Lucesole M; Sparaventi G; Piccaluga PP; Guernaccini E; Agostinelli F; Isidori A
Leuk Lymphoma; 2006 Dec; 47(12):2542-6. PubMed ID: 17169798
[TBL] [Abstract][Full Text] [Related]
7. Valganciclovir versus valaciclovir for prevention of alemtuzumab-induced cytomegalovirus reactivation: what are the implications for routine clinical practice?
Smolej L
Blood; 2008 Sep; 112(5):2167. PubMed ID: 18725576
[No Abstract] [Full Text] [Related]
8. Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab.
Vallejo C; Ríos E; de la Serna J; Jarque I; Ferrá C; Sánchez-Godoy P; Solano C; de la Cámara R; Rosell AI; Varela R; García MD; González-Barca E; López J; Pérez E; Ferrer S; Casado LF; Vázquez L; Villalón L; García-Marco JA
Expert Rev Hematol; 2011 Feb; 4(1):9-16. PubMed ID: 21322774
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia.
Nguyen DD; Cao TM; Dugan K; Starcher SA; Fechter RL; Coutre SE
Clin Lymphoma; 2002 Sep; 3(2):105-10. PubMed ID: 12435283
[TBL] [Abstract][Full Text] [Related]
10. Progress with alemtuzumab in chronic lymphocytic leukemia: Update from the 2003 meeting of the american society of hematology.
Lee D
Clin Lymphoma; 2004 Mar; 4(4):217-9. PubMed ID: 15072612
[No Abstract] [Full Text] [Related]
11. Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab.
O'Brien SM; Keating MJ; Mocarski ES
Clin Lymphoma Myeloma; 2006 Sep; 7(2):125-30. PubMed ID: 17026823
[TBL] [Abstract][Full Text] [Related]
12. Successful oral valganciclovir treatment of cytomegalovirus infection during Campath-1H therapy.
González H; Vernant JP; Caumes E
Leukemia; 2005 Mar; 19(3):478. PubMed ID: 15618954
[No Abstract] [Full Text] [Related]
13. The role of alemtuzumab in the treatment of chronic lymphocytic leukemia.
Zent CS
Leuk Lymphoma; 2008 Feb; 49(2):175-6. PubMed ID: 18231900
[No Abstract] [Full Text] [Related]
14. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
Robak T
BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab--double jeopardy.
Mulligan SP
Leuk Lymphoma; 2007 Oct; 48(10):1885-7. PubMed ID: 17917953
[No Abstract] [Full Text] [Related]
16. Successful treatment of steroid resistant autoimmune thrombocytopenia associated with chronic lymphocytic leukemia with alemtuzumab.
Ammatuna E; Marino C; Mitra ME; Calvaruso G; Iannitto E
Eur J Haematol; 2004 Sep; 73(3):225-6. PubMed ID: 15287923
[No Abstract] [Full Text] [Related]
17. DAT-negative hemolytic anemia in a chronic lymphocytic leukemia patient treated with alemtuzumab.
d'Arena G; de Filippi R; Pinto A
Leuk Lymphoma; 2007 Mar; 48(3):625-7. PubMed ID: 17454610
[No Abstract] [Full Text] [Related]
18. Alemtuzumab: a new option for refractory chronic lymphocytic leukemia?
Smith JA
Cancer Pract; 2001; 9(4):211-3. PubMed ID: 11879313
[No Abstract] [Full Text] [Related]
19. Management of infections in patients with chronic lymphocytic leukemia treated with alemtuzumab.
Elter T; Vehreschild JJ; Gribben J; Cornely OA; Engert A; Hallek M
Ann Hematol; 2009 Feb; 88(2):121-32. PubMed ID: 18682948
[TBL] [Abstract][Full Text] [Related]
20. Remission induction using alemtuzumab can permit chemotherapy-refractory chronic lymphocytic leukemia (CLL) patients to undergo allogeneic stem cell transplantation.
Knauf W; Rieger K; Blau W; Hegenbart U; Von Gruenhagen U; Niederwieser D; Thiel E
Leuk Lymphoma; 2004 Dec; 45(12):2455-8. PubMed ID: 15621759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
